FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112391182> ?p ?o ?g. }

• W3112391182 endingPage "1728" @default.
• W3112391182 startingPage "1720" @default.
• W3112391182 abstract "Abstract To assess the influence of graft-versus-host disease (GVHD) on recurrent leukemia and survival after allogeneic marrow transplantation, we studied 1,202 patients with acute nonlymphocytic leukemia (ANL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) given unmodified marrow grafts from HLA- identical siblings. Proportional hazards regression models using acute GVHD and chronic GVHD as time-dependent covariates demonstrated a significant association of GVHD with a decreased relative risk (RR, 0.33 to 0.42) of relapse in patients with ANL, ALL, and CML transplanted in advanced disease. Among patients developing either acute or chronic GVHD, treatment failure (that is, mortality or relapse) was decreased in patients with ALL transplanted in relapse (RR = 0.70, P less than .033) and CML in blast crisis (RR = 0.37, P less than .009). This effect was independent of age, sex, preparative regimen, GVHD prophylaxis, or length of follow-up. Five-year actuarial estimates were derived for the subset of 657 patients who survived in remission 150 days after transplant and were at risk for development of chronic GVHD. Among patients with ANL in first remission or CML in chronic phase, GVHD had an adverse effect on survival and no apparent influence on relapse. Among patients with ANL and ALL transplanted in relapse, the probability of relapse after day 150 was 74% without [corrected] GVHD, 45% with acute and chronic GVHD, 35% with [corrected] only acute GVHD, and 34% with only chronic GVHD (P less than .001). Actuarial survival in these four GVHD groups was 25%, 34%, 59%, and 62%, respectively (P less than .009). Among patients with CML in acceleration or blast crisis, the probability of relapse after day 150 was 65% without GVHD and 36% with acute and/or chronic GVHD (P less than .017). We conclude that acute and chronic GVHD were associated with a durable antileukemic effect and improved survival in patients transplanted in advanced stages of ALL and CML." @default.
• W3112391182 created "2020-12-21" @default.
• W3112391182 creator A5011254051 @default.
• W3112391182 creator A5020301269 @default.
• W3112391182 creator A5020910879 @default.
• W3112391182 creator A5037247107 @default.
• W3112391182 creator A5056405520 @default.
• W3112391182 creator A5060783496 @default.
• W3112391182 creator A5070624070 @default.
• W3112391182 creator A5085484980 @default.
• W3112391182 creator A5085787488 @default.
• W3112391182 creator A5089494498 @default.
• W3112391182 date "1989-05-01" @default.
• W3112391182 modified "2023-10-14" @default.
• W3112391182 title "Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia [published erratum appears in Blood 1989 Aug 15;74(3):1180]" @default.
• W3112391182 cites W107728909 @default.
• W3112391182 cites W143215620 @default.
• W3112391182 cites W1490838907 @default.
• W3112391182 cites W1522048276 @default.
• W3112391182 cites W1539774679 @default.
• W3112391182 cites W1548609628 @default.
• W3112391182 cites W1562876511 @default.
• W3112391182 cites W1596160021 @default.
• W3112391182 cites W1597544321 @default.
• W3112391182 cites W1602008817 @default.
• W3112391182 cites W1867426767 @default.
• W3112391182 cites W1905977830 @default.
• W3112391182 cites W1944382470 @default.
• W3112391182 cites W1965979673 @default.
• W3112391182 cites W1979300931 @default.
• W3112391182 cites W198186331 @default.
• W3112391182 cites W1992401639 @default.
• W3112391182 cites W2003272849 @default.
• W3112391182 cites W2007905422 @default.
• W3112391182 cites W2014247167 @default.
• W3112391182 cites W2018535826 @default.
• W3112391182 cites W2033980243 @default.
• W3112391182 cites W2041055738 @default.
• W3112391182 cites W2062442371 @default.
• W3112391182 cites W2067480394 @default.
• W3112391182 cites W2084886561 @default.
• W3112391182 cites W2113989770 @default.
• W3112391182 cites W2117983550 @default.
• W3112391182 cites W2264531153 @default.
• W3112391182 cites W2330491673 @default.
• W3112391182 cites W2337969406 @default.
• W3112391182 cites W2396957136 @default.
• W3112391182 cites W2400068632 @default.
• W3112391182 cites W2403701385 @default.
• W3112391182 cites W2412019915 @default.
• W3112391182 cites W2412055789 @default.
• W3112391182 cites W2417408391 @default.
• W3112391182 cites W2417914160 @default.
• W3112391182 cites W2419538306 @default.
• W3112391182 cites W2438498684 @default.
• W3112391182 cites W2576986565 @default.
• W3112391182 cites W33772365 @default.
• W3112391182 cites W5387557 @default.
• W3112391182 cites W975735119 @default.
• W3112391182 cites W2470092782 @default.
• W3112391182 cites W2995133996 @default.
• W3112391182 doi "https://doi.org/10.1182/blood.v73.6.1720.1720" @default.
• W3112391182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2653460" @default.
• W3112391182 hasPublicationYear "1989" @default.
• W3112391182 type Work @default.
• W3112391182 sameAs 3112391182 @default.
• W3112391182 citedByCount "593" @default.
• W3112391182 countsByYear W31123911822012 @default.
• W3112391182 countsByYear W31123911822013 @default.
• W3112391182 countsByYear W31123911822014 @default.
• W3112391182 countsByYear W31123911822015 @default.
• W3112391182 countsByYear W31123911822016 @default.
• W3112391182 countsByYear W31123911822017 @default.
• W3112391182 countsByYear W31123911822018 @default.
• W3112391182 countsByYear W31123911822019 @default.
• W3112391182 countsByYear W31123911822020 @default.
• W3112391182 countsByYear W31123911822021 @default.
• W3112391182 countsByYear W31123911822022 @default.
• W3112391182 countsByYear W31123911822023 @default.
• W3112391182 crossrefType "journal-article" @default.
• W3112391182 hasAuthorship W3112391182A5011254051 @default.
• W3112391182 hasAuthorship W3112391182A5020301269 @default.
• W3112391182 hasAuthorship W3112391182A5020910879 @default.
• W3112391182 hasAuthorship W3112391182A5037247107 @default.
• W3112391182 hasAuthorship W3112391182A5056405520 @default.
• W3112391182 hasAuthorship W3112391182A5060783496 @default.
• W3112391182 hasAuthorship W3112391182A5070624070 @default.
• W3112391182 hasAuthorship W3112391182A5085484980 @default.
• W3112391182 hasAuthorship W3112391182A5085787488 @default.
• W3112391182 hasAuthorship W3112391182A5089494498 @default.
• W3112391182 hasBestOaLocation W31123911821 @default.
• W3112391182 hasConcept C126322002 @default.
• W3112391182 hasConcept C203014093 @default.
• W3112391182 hasConcept C2776863199 @default.
• W3112391182 hasConcept C2776960273 @default.
• W3112391182 hasConcept C2778461978 @default.
• W3112391182 hasConcept C2779972918 @default.
• W3112391182 hasConcept C2780007613 @default.

• next